-
The Health and Health Commission has notified clinics and clinics that more than 500 kinds of drugs can be used
Time of Update: 2022-02-20
02 Variation 2: Rearranged and combined into twenty-two categories In addition to the increase in the total number, the drugs in the "Catalogue" were rearranged and combined again .
13 new antihypertensive drugs and diabetes The number of patients with hypertension also increased.
-
1,497 county-level hospitals will comprehensively upgrade grass-roots equipment purchases
Time of Update: 2022-02-20
2. 586 billion yuan: used to support the capacity building of county-level medical and health institutions and the pilot work on the construction of regional medical centers led by the National Development and Reform Commission .
-
New coronavirus nucleic acid 20-in-1 mixed detection technical specifications released
Time of Update: 2022-02-20
The "Specification" pointed out that the 20-in-1 mixed detection technology (referring to the method of collecting 20 swabs collected from 20 people in one collection tube for nucleic acid detection) can greatly improve the detection efficiency and is more suitable for large-scale populations.
-
Capital has "entered" Internet medical care how to avoid industry crisis?
Time of Update: 2022-02-20
"After several years of development, coupled with the promotion of the new crown epidemic, capital giants have 'entered the game', and Internet hospitals have entered the 'peak season' of licensing, but some problems and drawbacks have gradually been exposed in the process of development.
-
Rectification of online purchases and concealment of the national lowest price will be dealt with
Time of Update: 2022-02-20
Any pharmaceutical enterprise that conceals the lowest price in the country, is listed on the Internet with less than five provincial prices, and fails to complete the mapping between the original Sichuan serial number and the national medical insurance consumables code mapping, etc.
-
The first domestic 1.1 class anti-ED innovative drug exhibition hard core strength!
Time of Update: 2022-02-20
Academician Guo Yinglu, academician of the Chinese Academy of Engineering and leader of the Chinese Department of Urology and Andrology, said frankly that the successful listing of AIRIS® Addenafil Citrate represents a qualitative leap in the innovation and scientific research strength of domestic pharmaceutical companies, and contributes to the promotion of Chinese men's health.
-
Blockbuster biological drugs are included in the collection!
Time of Update: 2022-02-20
Compared with the previous draft for comments, the scope of the Guangdong Alliance’s centralized procurement in the official document has been further expanded, covering 276 chemicals and therapeutic biological products in the National Medical Insurance Drug Catalog with high consumption and high purchase amount, including human blood.
-
Capital favors multiple policy support on the track——Analysis of the listing situation of my country's medical device companies in 2021
Time of Update: 2022-02-20
The distribution pattern of listing is clear IVD is still the most popular According to the statistics of Zhongcheng Medical Device Research Institute, among the 37 newly listed companies, there are 17 in the field of in vitro diagnosis (IVD), and the number and proportion have increased significantly compared with the previous year.
-
How does Chinese patent medicine enter the DRG/DIP payment plan of western medical institutions
Time of Update: 2022-02-20
In fact, how to enter the DRG/DIP payment scheme of western medicine medical institutions is the biggest challenge for Chinese patent medicine companies in 2022 .
However, how proprietary Chinese medicines can enter the DRG/DIP payment scheme of Western medical institutions is a must for Chinese patent medicine companies in 2022.
-
AbbVie, AZ, Pfizer and other giants are under pressure: forging future competitiveness, where is the bet?
Time of Update: 2022-02-20
In fact, in the past two years, safety issues have emerged one after another with JAK inhibitors: in December 2021, in addition to AbbVie's Rinvoq, Pfizer's Xeljanz and Eli Lilly's Olumiant are also required to use new safety warnings and restrictions label .
-
Yiling's 13 innovative traditional Chinese medicines are deeply cultivated in the cardiovascular and cerebrovascular, cold and respiratory markets
Time of Update: 2022-02-20
In the field of cardiovascular and cerebrovascular diseases, Yiling Pharmaceutical has deployed three innovative patented traditional Chinese medicines: Tongxinluo Capsule, Shensong Yangxin Capsule and Qili Qiangxin Capsule.
-
State Food and Drug Administration: Medical devices such as Kangwei De, Bonmei Orthopedics, Edwards are being recalled
Time of Update: 2022-02-20
reported that due to a specific model and a specific batch of products, there was an error in the expiration date on the product label, the manufacturer Edwards Lifesciences LLC voluntarily recalled the valvuloplasty ring Tricuspid Annuloplasty Ring (Registration No.
-
The production reduction of Xiangfu attracts attention, and the price continues to rise!
Time of Update: 2022-02-20
In the market, the price of Cymbidium fragrans produced in Guangdong is around 11 yuan.
. In 2020, the prices of most varieties in the Chinese herbal medicine market will increase, and the variety of Cyperus officinalis has also improved with the big market, and the overall attention has increased.
-
The State Food and Drug Administration Announces Matters Concerning Strengthening the Administration of Radioactive Drugs
Time of Update: 2022-02-20
When a medical institution prepares a positron-based radioactive drug for record, the inspection of three consecutive batches of samples of the product to be produced and the review of the quality standard shall be undertaken by the drug inspection agency that complies with the relevant provisions of the "Administrative Measures for Radioactive Drugs" .
-
Soaring 400% injection!
Time of Update: 2022-02-20
Sales of Neostigmine Injections in China's Public Medical Institutions in Recent Years (Unit: 100 million yuan) Source: China's Public Medical Institutions' Terminal Competitive Landscape According to data from Minet.
Among them, the production enterprises of neostigmine methylsulfate injection are Shanghai Xinyi Jinzhu Pharmaceutical Co.
-
The "medium cure rate" is linked to medical insurance payment!
Time of Update: 2022-02-20
Zhejiang implements the inheritance, innovation and development of traditional Chinese medicine, which points out that the comprehensive implementation of "medium treatment rate" in all regions is linked to medical insurance payment.
-
Ascletis, Junshi, and Genting share prices collectively break out, how far can the new crown oral drug concept stocks go?
Time of Update: 2022-02-20
In fact, in recent days, the stock prices of many domestic pharmaceutical companies that have deployed oral new crown drugs have generally shown a continuous upward trend .
-
my country's orthopedic medical device industry ushered in a high degree of prosperity
Time of Update: 2022-02-20
5 billion, accounting for 9% of the total global medical device market sales .
Due to factors such as high R&D thresholds, complex production processes, difficult market access, and strict quality supervision, the early domestic artificial orthopaedic spine and joint implant manufacturers developed relatively slowly .
-
The official clarification that opening a pharmacy must follow the spatial layout requirements
Time of Update: 2022-02-20
Hubei Food and Drug Administration requires that when drug supervision and management departments at all levels conduct supervision and inspection, if they find that social pharmacies are engaged in drug retail activities that are not suitable for their pharmaceutical service capabilities, they should immediately take administrative measures.
-
Will the next price drop for centralized drug procurement be more than 50%?
Time of Update: 2022-02-20
Bidding is the process of making full use of the competition mechanism of the market, through which the bidder adopts a price reduction strategy to defeat the opponent in order to win the bid and achieve sales, so as to achieve the purpose of low-cost procurement .
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
